Related Experiment Video
Updated: Apr 6, 2026
07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.5K
Recent progress on small vessel disease with cognitive impairment
Li Gong1, Xue-Yuan Liu1, Min Fang1
1Department of Neurology, Shanghai Tenth People Hospital, Tongji University, School of Medicine China.
Summary
Early diagnosis of vascular cognitive impairment (VCI) is crucial for preventing vascular dementia (VaD). This review covers VCI pathophysiology, biomarkers, and treatments for better outcomes.
Area of Science:
- Neurology
- Neuroscience
- Internal Medicine
Background:
- Vascular cognitive impairment (VCI) encompasses cognitive deficits resulting from cerebrovascular diseases.
- Early detection and intervention are key to managing VCI and preventing progression to vascular dementia (VaD).
Purpose of the Study:
- To review current research on the pathophysiology of VCI.
- To summarize advancements in VCI biomarkers for early diagnosis.
- To discuss therapeutic strategies for managing VCI.
Main Methods:
- Literature review of recent studies on VCI.
- Analysis of research on VCI pathophysiology and vascular factors.
- Synthesis of data on diagnostic biomarkers and treatment options for VCI.
Main Results:
- VCI presents with varying degrees of cognitive dysfunction due to vascular factors.
- Understanding pathophysiology aids in identifying therapeutic targets.
- Emerging biomarkers show promise for early VCI detection.
Conclusions:
- VCI management requires a multi-faceted approach.
- Further research into pathophysiology and biomarkers can improve VCI outcomes.
- Timely intervention can mitigate cognitive decline and potentially reverse impairment.
Related Concept Videos
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:30Cognitive Development During Adulthood
1.2K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.2K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
681
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
681
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
755
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
755